Trial Profile
Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD Treatment
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Molindone (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 19 Oct 2020 Status changed from suspended to discontinued.
- 22 Nov 2019 Planned End Date changed from 20 Dec 2019 to 20 Dec 2021.
- 22 Nov 2019 Planned primary completion date changed from 29 Jul 2019 to 29 Jul 2020.